my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Evotec AG announced that Evotec and Dow AgroSciences (DOW) have entered into a research collaboration with the objective of leveraging Evotec's chemical proteomics services to support compounds in development at Dow AgroSciences. To this end, Evotec will perform chemical proteomics services (Cellular Target Profiling) to de-convolute phenotypic screening results obtained by Dow.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We look forward to working with Dow AgroSciences on this project. This collaboration highlights the broad applicability of Evotec's industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context.'
Evotec to realign Discovery Chemistry Operations
Evotec AG announced that it will close its Chemistry Operations in Thane, India. All chemistry efforts will now be performed at its Abingdon (UK) facility, answering to an increasing requirement to operate closer to the principal R&D laboratories of our major customers. All project work in ... more
Evotec AG announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. The contract covers a period of five years and has a total value of up to EUR7.7 million (approx. USD 10 million).Under the agreement Evotec, through its San Francisco ope ... more
PerkinElmer Completes Acquisition of Euroscreen Products SA And Evotec Technologies
PerkinElmer, Inc. reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis and High Content Screening (HCS). In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen ... more
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In a ... more
